Effects of acute hypoventilation and hyperventilation on exhaled carbon monoxide measurement in healthy volunteers by Cavaliere, Franco et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Pulmonary Medicine
Open Access Research article
Effects of acute hypoventilation and hyperventilation on exhaled 
carbon monoxide measurement in healthy volunteers
Franco Cavaliere*1, Carmen Volpe1, Riccardo Gargaruti1, Andrea Poscia2, 
Michele Di Donato2, Giovanni Grieco2 and Umberto Moscato2
Address: 1Institute of Anaesthesia and Intensive Care, Catholic University of the Sacred Heart, Rome, Italy and 2Institute of Hygiene, Catholic 
University of the Sacred Heart, Rome, Italy
Email: Franco Cavaliere* - f.cavaliere@rm.unicatt.it; Carmen Volpe - volpe.carmen@libero.it; Riccardo Gargaruti - riccardo.gargaruti@libero.it; 
Andrea Poscia - andreaposcia@libero.it; Michele Di Donato - michele.didonato@edu.rm.unicatt.it; Giovanni Grieco - giovanni.grieco@ieo.it; 
Umberto Moscato - umoscato@rm.unicatt.it
* Corresponding author    
Abstract
Background: High levels of exhaled carbon monoxide (eCO) are a marker of airway or lung
inflammation. We investigated whether hypo- or hyperventilation can affect measured values.
Methods: Ten healthy volunteers were trained to achieve sustained end-tidal CO2 (etCO2)
concentrations of 30 (hyperventilation), 40 (normoventilation), and 50 mmHg (hypoventilation). As
soon as target etCO2 values were achieved for 120 sec, exhaled breath was analyzed for eCO with
a photoacoustic spectrometer. At etCO2 values of 30 and 40 mmHg exhaled breath was sampled
both after a deep inspiration and after a normal one. All measurements were performed in two
different environmental conditions: A) ambient CO concentration = 0.8 ppm and B) ambient CO
concentration = 1.7 ppm.
Results:  During normoventilation, eCO mean (standard deviation) was 11.5 (0.8) ppm; it
decreased to 10.3 (0.8) ppm during hyperventilation (p < 0.01) and increased to 11.9 (0.8) ppm
during hypoventilation (p < 0.01). eCO changes were less pronounced than the correspondent
etCO2 changes (hyperventilation: 10% Vs 25% decrease; hypoventilation 3% Vs 25% increase).
Taking a deep inspiration before breath sampling was associated with lower eCO values (p < 0.01),
while environmental CO levels did not affect eCO measurement.
Conclusions:  eCO measurements should not be performed during marked acute
hyperventilation, like that induced in this study, but the influence of less pronounced
hyperventilation or of hypoventilation is probably negligible in clinical practice
Background
In the human body, carbon monoxide (CO) has two ori-
gins: the exogenous source is the absorption from tobacco
smoke and polluted air, the endogenous one is the break-
down of heme molecules by heme oxidase (HO) [1,2].
Exogenous CO increases in relation with the exposure to
tobacco smoke and polluted air. Endogenous CO grows
in the case of increased heme catabolism, caused by
hemolysis, or by the synthesis of the isoenzyme HO-1,
also known as stress-inducible heat shock protein 32,
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which is upregulated by a variety of stressors, such as
cytokines, hypoxia, and reactive oxygen species. In all
cases, the increased CO in the body results in increased
CO levels in exhaled breath (eCO). Consequently eCO
measurements may be useful to evaluate smoking absti-
nence [3], exposition to polluted air [4], oxidative stress
caused by anaesthesia or surgery [5], severe sepsis [6], sta-
ble asthma and asthma exacerbations [7,8], chronic
obstructive pulmonary disease (COPD) [9], hemolysis in
children with sickle cell disease [10], and upper [11] and
lower airway inflammation [12]. Table 1 reports some
examples of eCO levels in smoking healthy subjects and
patients with significant issues.
Independently from the amount of CO produced by a
patient, his/her eCO levels may be influenced by the con-
dition in which measurements are performed. For
instance eCO can temporarily increase during oxygen
therapy because hyperoxia facilitates CO release from car-
boxyhemoglobin [13-15]. Acute hyperventilation may
decrease eCO values by dilution; in addition theoretical
models suggest that alveolar ventilation may affect CO
stores by varying the partial pressure of this gas in the alve-
oli and consequently in blood and tissues. In that case a
proportionate amount of CO should be released or stored
in order to achieve a new equilibrium [16]. This process
can take several hours, meanwhile eCO measures may be
poorly representative of CO production.
Changes of ventilatory pattern can potentially occur near
eCO measurements. Patients can be induced to hyperven-
tilate by the procedure of breath sampling itself [17]; fur-
thermore, acute ventilatory changes are not infrequent in
asthma exacerbations, sepsis, or during assisted mechani-
cal ventilation. The aim of this study was to evaluate
whether acute hypo- or hyperventilation can affect eCO
measurements. Secondarily, we evaluated the influence of
environmental CO and breath sampling procedure on
eCO measurements.
Methods
The study was carried out in the Catholic University of the
Sacred Heart in Rome. Measurements were performed in
duplicate in two laboratories situated in different build-
ings, the first one in the Surgical Intensive Care Unit (A),
the second in the institute of Hygiene (B). After the
approval of local Ethic Committee and informed consent,
10 healthy volunteers (5 men and 5 women) were
enrolled in the study. Table 2 reports theirs anthropomet-
ric and lung functions values.
Exclusion criteria were: a) active or passive tobacco
smoke, b) chronic respiratory diseases, and c) acute respi-
ratory diseases occurred in the past four months.
In each subject, eCO was measured at end tidal CO2
(etCO2) values of 30, 40, and 50 mmHg in A and B set-
tings. At etCO2 values of 30 and 40 mmHg, exhaled gases
were collected both after normal inspiration and after
maximum inspiration. Measurements at 50 mmHg were
only performed after normal inspiration in order to avoid
a brisk etCO2  decrease. Measurement were performed
twice in each setting.
Subjects were asked to breath through a mouth piece in a
device (figure 1) including a) a HME bacterial/viral filter
(DAR Barrierbac S, Mallinkrodt DAR, Italy); b) the cell of
the main stream capnometer CosmoPlus mod. 8100
(Novametrix Medical Systems Inc. Connecticut, USA) in
order to measure etCO2; c) a tracheal tube (Mallinkrodt
Inc, UK) with an internal diameter of 9 mm in order to
prevent any risk of collecting external air during sampling
for eCO measurements. The HME filter (internal volume
35 mL) protected the capnometer cell from condensation
Table 1: Exhaled CO levels in smoking healthy subjects and patients with significant issues.
Authors Diseases or smoking Exhaled CO level (ppm) N. Subjects
Mean Range or S.D. or 95% C.I.
Deveci et al (2004) [27] Smoking 17.13 ± 8.5 243
Carpagnano et al (2003)[28] Smoking 16.70 ± 5.5 31
Montuschi et al. (2001) [9] COPD 7.40 ± 1.9 15
Montuschi et al. (2001) [9] COPD + Smoking 20.0 ± 2.6 15
Biernacki et al (2001) [12] LRTI 5.20 ± 0.5 35
Yamaya et al (1998) [29] URTI 5.60 ± 0.4 20
Ohara Y et al (2006) [7] Asthma 5.10 ± 0.4 22
Kiyoshi et al (1997) [30] Asthma 5.60 ± 0.6 12
Paredi et al (1999) [31] CF 6.70 ± 0.6 29
Horvath et al. (2003) [32] Bronchiectasis 5.00 3.0 - 15.0 31
De Las Heras et al (2003) [33] SBP 7.00 ± 0.5 9
COPD chronic obstructive pulmonary disease; LRTI lower respiratory tract infection; URTI upper respiratory tract infections; CF cystic fibrosis; 
SBP spontaneous bacterial peritonitis;BMC Pulmonary Medicine 2009, 9:51 http://www.biomedcentral.com/1471-2466/9/51
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and allowed gas sampling for eCO measurements from
the capnometry port. Initially, subjects were trained: a) to
perform a prolonged expiration that lasted not less than
16 seconds, and b) to hypoventilate or hyperventilate in
order to maintain a target etCO2 value on the display of
the capnometer. Successively, they were asked to achieve
the etCO2 values of 30, 40, and 50 mmHg in random
sequence. As soon as the target etCO2 value was main-
tained within a range of ± 2 mmHg for 120 sec, the
patients were asked to perform a prolonged expiration
and exhaled gases were sampled for eCO analysis.
Breath samples were suctioned through a tube 1 m long
and with an internal diameter of 3 mm by the photoa-
coustic spectrometer utilized for CO analysis; 80 mL were
collected in 10 sec. Sampling was started by an operator
three seconds after the beginning of a prolonged expira-
tion lasting 16 seconds or more. It was initially assessed
with capnography that an interval of two seconds was
long enough to avoid anatomical dead space sampling. As
a further precaution, the operator looked at the capno-
gram displayed by Cosmo plus during gas sampling; if
sampling started before phase C (alveolar plateau), the
procedure was repeated. The etCO2 value measured before
(pre-test etCO2) and during (test etCO2) each eCO meas-
urements and the peripheral arterial oxygen saturation
(SpO2) were registered. Before each session of the study,
the capnometer was calibrated and environmental CO
concentration was measured.
eCO was measured with a photo-acoustic spectrometer
field gas monitor Innova 1312 (LumaSense Technologies
A/S, Denmark) equipped with a filter for CO analysis and
with the software 7300 (LumaSense Technologies A/S,
Denmark). The instrument is based on the photo-acoustic
effect in the infra-red wave-lenghts[18]. Sampled CO
absorbs light energy at a specific wave length, emitted by
spectrometer, and transforms it into kinetic energy; this
process causes local heating and pressure waves resulting
in sounds that can be detected by a microphone. The
photo-acoustic field gas monitor suctions gaseous sam-
ples by a pump to fill the photo-acoustic cell in which
measurements are performed. Dead space, water-vapor's
(or other gases) and temperature interference were auto-
matically compensated. Detection limit was ≥ 0.02 ppm
(part per million), with Sample Integration Times (S.I.T.)
fixed at 5 seconds and multiplication factor 1.
The statistical analysis was carried out with the software
"Statistica for Windows" (StatSoft Inc, USA) and STATA
Intercooled v. 9.2 software for MacIntosh (Stata Co.; Col-
lege Station Lakewag, TX, USA). Values are reported as
means (standard deviations). Major deviations from nor-
mal distribution were ruled out by graphic inspection and
by Shapiro-Wilks's test. The Kruskal-Wallis (K-W) equal-
ity-of-populations rank test (adjusted with Bonferroni at
level of significance p ≤ 0.05) was employed to assess real
difference of variation between lab A vs lab B.
Statistical analysis on eCO values was performed with
ANOVA for repeated measures; planned comparisons
were tested with linear contrasts. Factors taken into
account were setting (lab A Vs B) and etCO2 (30 Vs 40 Vs
50 mmHg); planned comparisons were hypoventilation
Vs normoventilation, hyperventilation Vs normoventila-
tion, normal inspirations Vs deep inspiration. ANOVA for
repeated measures was also applied to SpO2 values. The
Table 2: Anthropometric and lung function values as means 
(standard deviations) of the healthy volunteers enrolled in this 
study.
Men Women
AGE (anni) 31.40 (12.30) 28.60 (12.20)
BMI (Kg/m2) 24.19 (1.41) 20.88 (3.10)
FEV1(L) 3.76 (0.40) 2,62 (0.64)
FVC (L) 4.23 (0.48) 3.02 (0.67)
FEV1/FVC (%) 88.95 (1.85) 86.57 (2.10)
PFER (L/s) 8.57(0.96) 5.32 (1.33)
BMI body mass index; FEV1 forced expiratory volume in one second; 
FVC forced vital capacity; FEV1/FVC forced expiratory volume in one 
second/forced vital capacity; PEFR peak expiratory flow rate;
The device assembled for breath sampling and etCO2 meas- urement Figure 1
The device assembled for breath sampling and 
etCO2 measurement. The HME filter (A); the cell of the 
main stream capnometer CosmoPlus mod. 8100 (Novame-
trix Medical Systems Inc. Connecticut, USA) in order to 
measure etCO2 (B); a Mallinkrodt tracheal tube with an 
internal diameter of 9 mm in order to prevent any risk of 
collecting external air during sampling for eCO measure-
ments (C). The tube 1 m long and with an internal diameter 
of 3 mm through which breath samples were suctioned (D).BMC Pulmonary Medicine 2009, 9:51 http://www.biomedcentral.com/1471-2466/9/51
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factor taken into account was etCO2; planned compari-
sons were hypoventilation Vs normoventilation and
hyperventilation Vs normoventilation. Finally, pre-test
and test etCO2 values were compared with paired t-test.
Results
eCO analysis showed a good level of reproducibility. The
mean difference between duplicate measurements was
0.11 (0.20) ppm. Environmental CO concentration was
0.8 ppm in lab A and 1.7 ppm in lab B.
eCO values are reported in table 3. In comparison with
normoventilation, eCO values were lower during hyper-
ventilation and higher during hypoventilation (p < 0.01
in both cases); difference was more pronounced between
normo- and hyperventilation (mean value: 1.2 ppm) than
between normo- and hypoventilation (mean value: 0.4
ppm). No significant difference was observed between
measurements performed in lab A and B (K-W test), while
measured eCO levels were significantly lower when gas
sampling was performed after a deep inspiration than
after a normal inspiration (p < 0.01).
Table 4 reports SpO2 and etCO2 values. In comparison
with normoventilation, SpO2 increased during hyperven-
tilation and decreased during hypoventilation (p < 0.01 in
both cases). Test etCO2 registered during the prolonged
expiration for gas sampling were significantly higher than
pre-test etCO2 (p < 0.01).
Discussion
In general ventilation patterns can influence quantifica-
tion of volatile analytes in exhaled breath and should be
controlled to ensure representative analyses [17]. In this
study we evaluated whether acute hypo- or hyperventila-
tion can significantly influence eCO measurements. This
hypothesis was only partially confirmed because hyper-
ventilation decreased eCO, but to a much lesser extent
than etCO2; in practice, eCO decreased by 10% while
etCO2 decreased by 25%. Hypoventilation had an even
lesser effect, causing a small and clinically negligible eCO
increase (3%) while etCO2 increased by 25%. We also
found that eCO measurements were not affected by envi-
ronmental CO, but decreased slightly if a deep inspiration
is taken before breath sampling.
Changes of ventilatory pattern are common in patients
affected by respiratory diseases, particularly during
mechanical ventilation; in addition, the procedure of
breath sampling itself may induce patients to hyperventi-
late [17]. Acute hypo- and hyperventilation cause propor-
tional changes of the levels of many analytes, such as CO2,
isoprene, and ethane, in exhaled breath [17-19]. By con-
trast our results point out that hypo- and hyperventilation
have small impact on eCO measurements; this is in agree-
ment with the observation reported by other Authors that
ventilatory changes affects eCO and etCO2  differently
[17].
Our results are apparently in contrast with theoretical pre-
dictions. In steady state, eCO is strictly correlated with the
endogenous production of CO and with carboxyhaemo-
globin blood levels [20], but these relationships are influ-
enced by alveolar ventilation, as well as by the
environmental CO levels, by the diffusing capacity of the
lung for CO, and by the oxygen partial pressure in pulmo-
nary capillaries [16]. By means of a mathematical model,
Cobourn and Coll calculated that doubling alveolar ven-
tilation from 4 to 8 liters per minute in a patient with a
normal CO production of 0.42 mL per hour would have
resulted in a 43% decrease of carboxyhaemoglobin, from
0.37 to 0.21% [16]; a corresponding variation can be
hypothesized for eCO. The smaller changes observed in
this study are possibly explained because calculations
were referred to the new steady state that may be achieved
only several hours after ventilatory variations. Cobourn
and Coll estimated that the half-life of the process was
about 7 hours [16], far longer than the half-life of CO2
store variations, which have been estimated around 70
minutes or less with animal models [21,22] and around
35 minutes in men [19]. The longer CO half-life may be
explained by the small amount of this gas released every
minute through the lungs in comparison with the stores
in the human body. Stored CO has been estimated at 10
mL, 8 of which are bound to hemoglobin [23]. The CO
released by a healthy man is about 0.4 mL per hours [21]
Table 3: Exhaled carbon monoxide values registered in laboratory A and B.
Et-CO2 target 30 mmHg (hyperventilation) 40 mmHg (normoventilation) 50 mmHg (hypoventilation)
Inspiration Normal Deep Normal Deep Normal
Lab A (0.8 ppm) 10.2(0.9) 9.6(0.8) 11.4(0.8) 10.7(0.8) 11.8(0.9)
Lab B (1.7 ppm) 10.3(0.7) 9.7(0.7) 11.6(0.8) 10.8(0.8) 11.9(0.7)
Total 10.3(0.8) 9.7(0.8) 11.5(0.8) 10.8(0.8) 11.9(0.8)
Means (standard  deviations) of exhaled carbon monoxide (eCO) values registered in laboratory A and B (environmental eCO level 0.8 and 1.7 
ppm, respectively). Values are reported as particles per milion (ppm)  .
Statistical analysis: ANOVA: LabA Vs Lab B non significant; hyperventilation Vs normoventilation p < 0.01; hyperventilation Vs normoventilation p < 
0.01; normal inspiration Vs deep inspiration p < 0.01.BMC Pulmonary Medicine 2009, 9:51 http://www.biomedcentral.com/1471-2466/9/51
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i.e. 7 μL per minute, which corresponds to about 0.07% of
body stores and 0.09% of blood content. Conversely, the
readily exchangeable CO2 stored in the body is about 14 L
[24] and the CO2  released is about 200-250 mL per
minute, which corresponds to about 1.4-1.8% of body
stores. As a consequence the stabilization of eCO and
blood carboxyhemoglobin levels after ventilatory changes
requires many hours. Hypothetically, if in this study
hypoventilation or hyperventilation had been prolonged
for a time interval long enough to approximate the steady
state, eCO changes would have possibly shown the same
magnitude of etCO2changes.
Our results stress the importance of standardizing the pro-
cedure for measuring eCO. We observed that taking a
deep or normal inspiration can affect eCO levels, other
Authors reported that measuring after a breath hold may
result in higher eCO values than sampling without breath
hold [25] In addition, our data suggest that, even in
healthy subjects, a deep expiration may recruit pulmonary
alveoli that are poorly represented in a normal expiration
since a significant difference was observed between etCO2
values measured immediately before (pre-test) and during
(test) breath sampling. Of note, pulmonary heterogeneity
strongly affects the relationship between eCO and CO-
Hb, [16] which is lost in patients affected by severe pul-
monary emphysema or airway obstruction [20,26].
A limit of our study is that we did not evaluate the effects
of prolonged ventilatory changes on eCO. In addition, we
measured CO values by a photoacoustic spectrometer. To
our knowledge this kind of instrument has not been uti-
lized for eCO measurement before. In this study photoa-
coustic spectrometer performed CO analysis with very
high sensitivity and precision on breath samples that were
representative of the entire exhaled breath. Theoretically
the eCO values obtained with our method may reflect a
wider alveolar population in comparison with the end
tidal values provided by electrochemical sensors that are
utilized for routine eCO measurements. These methodo-
logical differences may partly explain why the volunteers
enrolled in this study presented relatively high eCO values
for non-smokers compared with literature data (Table 5).
Other possible explanations were that all the subjects
lived in densely populated urban environment and were
consequently exposed to high levels of environmental CO
and that eCO values are characterized by large interindi-
vidual variability [4]; as a matter of fact, eCO levels similar
to those observed in this study have been reported in
healthy non smokers by other authors [14].
Conclusions
While eCO values are scarcely affected by hypoventilation
that occurs during measurement, hyperventilation should
be avoided because it significantly decreases eCO values.
Table 4: Exhaled carbon monoxide, end tidal CO2, and peripheral oxygen saturation.
Et-CO2 target 30 mmHg (hyperventilation) 40 mmHg (normoventilation) 50 mmHg (hypoventilation)
Inspiration Normal Deep Normal Deep Normal
eCO (ppm) 10.3 (0.8) 9.7 (0.8) 11.5 (0.8) 10.8 (0.8) 11.9 (0.8)
Pre-test etCO2 (mmHg) 29.4 (1.6) 28.7 (1.6) 39.4 (1.7) 39.2 (1.7) 49.1 (1.7)
Test etCO2 (mmHg) 37.8 (2.5) 35.6 (2.8) 46.1 (3.3) 43.0 (2.9) 51.6 (3)
SpO2 (%) 99 (1) 98 (1) 96 (2)
Means (standard deviations) of exhaled carbon monoxide (eCO) values, end tidal CO2 values measured before and during breath sampling 
(respectively pre-test etCO2 and test etCO2), and peripheral oxygen saturation (SpO2).
Statistical analysis. EtCO2: pre-test Vs test p < 0.01. SpO2: ANOVA p < 0.01; hyperventilation Vs normoventilation p < 0.01; hyperventilation Vs 
normoventilation p < 0.01.
Table 5: Exhaled carbon monoxide values in non smoking healthy subjects reported in literature.
Authors Exhaled CO level (ppm) N. Subjects
Mean Range or S.D. or 95% C.I.
Chatkin J. et al. (2007) [3] 4.30 ± 2.5 152
Cunnington and Hormbrey (2002) [34] 1.26 1.14-1.37 366
Deveci et al (2004) [27] 3.61 ± 2.15 55
Horvath et al. (2003) [32] 3.00 0.5-5.0 37
Laranjeira R. at al (2000) [35] 2.50 1.0 - 4.0 100
Montuschi et al. (2001) [9] 3.00 ± 0.3 10
Scharte et al. (2000) [36] 1.55 1.2-1.7 6BMC Pulmonary Medicine 2009, 9:51 http://www.biomedcentral.com/1471-2466/9/51
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Nonetheless light hyperventilation occurring during
measurements may be acceptable because eCO changes
are much less pronounced than ventilation changes
(reflected by etCO2).
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